Clinical trials: Glycemic Control for Diabetes Mellitus
Type 2 Diabetes Mellitus
Insulin Schemes for Type 2 Diabetes Control
The aim of the study is to determine differences in glycemic control between a basal-bolus scheme insulin and NPH scheme insulin in a population of hospitalized patients with type 2 diabetes in a Noncritical Care Facility in…
- Trial name
- NCT03350984
- Testing
- NPH insulin, Glargine and Lispro insulin
- Where
- Mexico
- Volunteers
- 75 people
- Sponsor
- Universidad de Guanajuato
Type 1 Diabetes Mellitus
Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes
This overall research goal will be to develop a mobile-based module to improve glycemic control during the menstrual cycle in women with Type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01653210
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Virginia
Diabetes Mellitus, High Blood Pressure
Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support
The objective of this study is to compare the effectiveness of a novel program-Family Support for Health Action (FAM-ACT) - to individual patient-focused diabetes self-management education and support (I-DSMES).
- Conditions
- Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
- Trial name
- NCT03812614
- Testing
- FAM ACT, I-DSMES
- Where
- 2 sites in United States
- Volunteers
- 444 people
- Sponsor
- University of Pittsburgh
Type 2 Diabetes Mellitus
A Study for Type 2 Diabetic Patients
The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level
- Trial name
- NCT00548808
- Testing
- Insulin lispro low mixture, Insulin glargine, Insulin lispro
- Where
- 25 sites in Australia, Brazil and 5 more
- Volunteers
- 426 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Hyperglycemia
Inpatient Closed-loop Glucose Control
The purpose of this study is to test an experimental medical device designed to automatically control blood sugar. This device was designed for use by patients with diabetes while they are in the hospital, and others who may…
- Trial name
- NCT01819844
- Testing
- Closed-loop blood glucose control
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Cystic Fibrosis-related Diabetes
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children…
- Trial name
- NCT03258853
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Achieving near-normoglycemia has been established as the main objective for most patients with type 1 diabetes (T1DM). However, insulin dosing is an empirical process and its success is highly dependent on the patients' and…
- Trial name
- NCT01550809
- Testing
- iBolus, tBolus (traditional bolus)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Type 1 Diabetes
"MyPlan" - Individualized Planned Eating Patterns for Adolescents With Type 1 Diabetes
The purpose of this study is to test the acceptability and effectiveness of an individualized eating strategy as part of diabetes self-management to improve glycemic levels among youth with type 1 diabetes (T1D) and suboptimal…
- Trial name
- NCT05147324
- Testing
- "MyPlan" - Individualized Planned Eating Pattern
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension…
- Trial name
- GETGOAL-MONO (NCT00905255)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients
To compare glycemic control and treatment satisfaction using a novel bolus insulin patch (Finesse) versus a pen for initiating and managing bolus insulin dosing in patients with T2DM not achieving glycemic targets on basal…
- Trial name
- NCT02542631
- Testing
- Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
- Where
- 52 sites in United States, France and 2 more
- Volunteers
- 278 people
- Sponsor
- Calibra Medical, Inc.
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-F1 (NCT00763451)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 484 people
- Sponsor
- Sanofi